Fig. 3

Upregulation of PD-1 expression on bone marrow T cells of AML patients at relapse after allogeneic SCT compared to diagnosis. Expression of CD244 (a, e), PD-1 (b, f), CD160 (c, g), and TIM-3 (d, h) was measured on bone marrow CD8⁺ (a–d) and CD4⁺ (e–h) T cells of 31 AML patients at diagnosis (AML_diag), 7 patients with an AML relapse after intensive chemotherapy (AML_rel), and 6 patients with an AML relapse after allogeneic SCT (AML_rel_allo) in comparison to 5 healthy controls (HC), and percentages of positive cells were depicted. Patient selection was limited to the age cohort >40 years. Statistical differences were calculated to HC and AML_diag. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001